Europe and Asia provide a safe haven as US stocks falter
Non-US big biopharma stocks led the way in the third quarter, suggesting that those looking for investment gains would do best to search further afield.
Does amount matter when it comes to a biotech IPO?
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
Mid cap device makers find rewards in cancer and diabetes
Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.
Big cap medtech comes roaring back
Exact Sciences finds that where there’s muck there’s brass, but specialisation does not work as well for Abiomed.
US big biotechs lag in the opening quarter of the year
A look at sector share prices in the opening three months of 2019 reveals a resurgent big pharma and a strong showing from the world’s other large drug makers, with US…
Biopharma in 2019 – navigating choppy waters
Vantage publishes its annual look ahead to 2019, examining the trends and issues that will shape biopharma in the coming year.
Biotech's big-bucks buybacks begin to burn
If big biotech cannot deliver innovation investors might start demanding shareholder payout plans that look more like big pharma's.
Big biopharma back in favour in the third quarter
Several large-cap drug stocks registered healthy gains across the third quarter of 2018, signalling investors' growing confidence in biopharma after a disappointing…
Fireworks among the small and mid-cap device makers
Smaller medtechs saw impressive share price growth in 2018, but not quite as good as the year before.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.